RB1 and small cell lung carcinoma: PARP inhibitors are a compelling class of drugs in the treatment of SCLC, with a mechanism of action that takes advantage of genomic instability and loss-of-function TP53/RB genomic alterations that challenge the cells’ ability to repair DNA.